MICROBIOME MODIFICATION AND IMPROVEMENT OF SIGNS AND SYMPTOMS OF COVID-19: ILEOCOLONIC-RELEASE NICOTINAMIDE IN A PROSPECTIVE, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL

Stefan Schreiber  1, 2     Georg H. Waetzig  1, 2, 3     Corinna Geisler  1, 2     Kristina Schlicht  1, 2     Sina Franzenburg  4     Víctor A. López-Agudelo  1, 2     Romina di Giuseppe  4     Daniel Pape  1     Thomas Bahmer  1     Michael Krawczak  2     Elisabeth Kokott  1     Oliver Harzer  5     Jan Kramer  6     Tammo von Schrenck  7     Felix Sommer  1, 2     Helena U. Zacharias  8     Jan Heyckendorf  1     Konrad Aden  1, 2     Regina Hollweck  9     Matthias Laudes  1, 2     Philip Rosenstiel  1, 2    
1 University Medical Center Schleswig-Holstein, Kiel, Germany
2 Kiel University, Kiel, Germany
3 CONARIS Research Institute AG, Kiel, Germany
4 Competence Network Intestinal Diseases, Kiel, Germany
5 Bioscientia Healthcare GmbH, Ingelheim, Germany
6 LADR GmbH MVZ Dr. Kramer & Kollegen, Geesthacht, Germany
7 Labor Dr. von Froreich GmbH, Hamburg, Germany
8 Peter L. Reichertz Institute for Medical Informatics, Hanover, Germany
9 Novustat GmbH, Wollerau, Switzerland

Conference
UEG Week 2023

Citation
United European Gastroenterology Journal 2023; 11 (Supplement 8)


Login to access library content

Login

Do you need help setting up your myUEG account?
Contact us at [email protected]

New to myUEG?

Create myUEG account

Social Sharing